Clinical Trial Detail

NCT ID NCT03488225
Title Hyper-CVAD in Combination With Inotuzumab Ozogamicin as Frontline Therapy for Adults With Acute Lymphocytic Leukemia
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

acute lymphoblastic leukemia

Therapies

Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate

Cytarabine + Leucovorin + Methotrexate

Inotuzumab ozogamicin

Ofatumumab

Rituximab

Cytarabine + Doxorubicin + Methotrexate + Vincristine Sulfate

Pegfilgrastim

Cyclophosphamide + Dexamethasone + Mesna

Age Groups: child adult

No variant requirements are available.